Gliquidone sodium
Based on 2 publication(s) in Google Scholar
Gliquidone sodium (AR-DF 26 sodium) can bind to the pancreatic β-cells and increases insulin release to regulate blood glucose levels. Gliquidone sodium significantly decreases LPS (HY-D1056)-induced proinflammatory responses and inhibits ERK/STAT3/NF-κB phosphorylation in BV2 microglial cells. Gliquidone sodium can suppress microgliosis, microglial hypertrophy mediated by LPS, and proinflammatory cytokine COX-2 and IL-6 levels in murine model. Gliquidone sodium also exhibits good anticancer activity in lung carcinoma cells. Gliquidone sodium has antioxidant property. Gliquidone sodium can be studied in research for type 2 diabetes and cancers.
For research use only. We do not sell to patients.
- CAS No.: 62783-47-5
- Formula: C27H33N3NaO6S
- Molecular Weight:550.63
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Gliquidone sodium
More
Biological Activity
Description
In Vitro
Gliquidone (Compound GQD) sodium (AR-DF 26 sodium) (100-300 μg/mL) exhibits low IC50 value in DPPH (236.84) and superoxide radical scavenging (174.20), suggesting a high antioxidant activity[2].
Gliquidone (0-200 μg, 24 h) sodium has anticancer activity against A549 human alveolar lung cancer cells with an IC50 of 93.49 μg/mL[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:A549
-
Concentration:12.5, 25, 50, 100, 200 μg
-
Incubation Time:24 h
-
Result:Exhibited a significant cytotoxic effect on human alveolar lung cancer cells.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6J mouse model of Parkinson’s disease[1]
-
Dosage:10, 20 mg/kg
-
Administration:Intraperitoneal injection (i.p.)
-
Result:Effectively downregulated LPS-mediated microgliosis and changes in microglial kinetics and morphology in mouse brain with 20 mg/kg.
Significantly decreased the LPS-induced increases in Iba-1 immunoreactivity, Iba-1-positive cells, and Iba-1-labeled area in the cortex and hippocampal CA1 and CA3 region with 20 mg/kg.
Significantly reduced the LPS-induced increases in Iba-1 intensity, Iba-1-positive cells, and Iba-1-labeled area only in the hippocampal CA3 region with 10 mg/kg.
Significantly reduces the LPS-induced increases in GFAP immunointensity and GFAP-positive cells in the cortex but not in the hippocampus.
Eliminated lipopolysaccharide-induced increases in COX-2 and IL-6 proinflammatory cytokine levels in wild-type mice.
Inhibited LPS-induced NLRP3 infllammasome activation.
Chemical Information
-
CAS No. 62783-47-5
-
Molecular Weight 550.63
-
Formula C27H33N3NaO6S
-
SMILES
[Na].O=C(NC1CCCCC1)NS(=O)(=O)C2=CC=C(C=C2)CCN3C(=O)C4=CC(OC)=CC=C4C(C3=O)(C)C
-
Synonyms
AR-DF 26 sodium
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Eur J Pharm Sci
Repurposing of FDA-approved drugs by targeting SIRT2 to alleviate inflammatory response and kidney injury. [Abstract]2025 Nov 1:214:107296. PMID: 41022315 -
Cancers (Basel)
2024 Nov 12;16(22):3807. PMID: 39594764
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Gliquidone sodium Related Classifications
HY-B1114A Related Classifications
Powered by Bioz